Eye Care-Focused Biopharma Firm SpyGlass Files for US IPO

SpyGlass Pharma Inc. filed for an initial public offering to help fund late-stage trials of its intraocular lens and drug delivery solutions to treat patients with chronic eye conditions such as glaucoma.

The Aliso Viejo, California-based firm had a net loss of $27.3 million for the nine months ended September 30, 2025, compared with net loss of $20.8 million a year earlier, according to its filing Friday with the US Securities and Exchange Commission. It had $106 million of cash and equivalents on hand as of Sept. 30.

SpyGlass has raised about $200 million in funding, most recently via ...